Suppr超能文献

内镜黏膜下隧道剥离术治疗食管浅表鳞癌及癌前病变的疗效及安全性。

Efficacy and safety of endoscopic submucosal tunnel dissection for superficial esophageal squamous cell carcinoma and precancerous lesions.

机构信息

Department of Gastroenterology and Hepatology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

Department of General Practice, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.

出版信息

World J Gastroenterol. 2018 Jul 14;24(26):2878-2885. doi: 10.3748/wjg.v24.i26.2878.

Abstract

AIM

To evaluate the clinical outcomes of patients who underwent endoscopic submucosal tunnel dissection (ESTD) for esophageal squamous cell carcinoma (ESCC) and precancerous lesions.

METHODS

ESTD was performed in 289 patients. The clinical outcomes of the patients and pathological features of the lesions were retrospectively reviewed.

RESULTS

A total of 311 lesions were included in the analysis. The en bloc rate, complete resection rate, and curative resection rate were 99.04%, 81.28%, and 78.46%, respectively. The ESTD procedure time was 102.4 ± 35.1 min, the mean hospitalization time was 10.3 ± 2.8 d, and the average expenditure was 3766.5 ± 846.5 dollars. The intraoperative bleeding rate was 6.43%, the postoperative bleeding rate was 1.61%, the perforation rate was 1.93%, and the postoperative infection rate was 9.65%. Esophageal stricture and positive margin were severe adverse events, with an incidence rate of 14.79% and 15.76%, respectively. No tumor recurrence occurred during the follow-up period.

CONCLUSION

ESTD for ESCC and precancerous lesions is feasible and relatively safe, but for large mucosal lesions, the rate of esophageal stricture and positive margin is high.

摘要

目的

评估内镜黏膜下隧道剥离术(ESTD)治疗食管鳞状细胞癌(ESCC)及癌前病变患者的临床疗效。

方法

对 289 例患者行 ESTD 治疗,回顾性分析患者的临床疗效及病变的病理特征。

结果

共纳入 311 处病变,整块切除率、完全切除率及治愈性切除率分别为 99.04%、81.28%和 78.46%。ESTD 手术时间为 102.4±35.1 min,平均住院时间为 10.3±2.8 d,平均费用为 3766.5±846.5 美元。术中出血率为 6.43%,术后出血率为 1.61%,穿孔率为 1.93%,术后感染率为 9.65%。食管狭窄和切缘阳性为严重不良事件,发生率分别为 14.79%和 15.76%。随访期间无肿瘤复发。

结论

ESTD 治疗 ESCC 及癌前病变是可行且相对安全的,但对于较大的黏膜病变,食管狭窄和切缘阳性的发生率较高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21b5/6048426/9796726bc4cb/WJG-24-2878-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验